Skip to main content

Advertisement

Table 3 Patient characteristics and results of survival analysis for primary glioblastoma patients when stratified by MGMT methylation status

From: MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

Overall survival   MGMT methylation status
  Total qMSP Pyrosequencing
   Methylated Unmethylated Methylated Unmethylated
Patients (n) 58 19 39 29 29
Male/Female 31/27 10/9 21/18 15/14 16/13
Mean agea (Standard deviation) 58.5 (9.1) 57.5 (8.7) 59.0 (9.3) 59.3 (8.5) 57.7 (9.7)
Median survivalb (Standard error) 13.1 (1.1) 17.6 (4.2) 12.2 (1.0) 16.1 (3.7) 11.5 (0.4)
2-years overall survival (%) (Standard error) 21.8 (0.06) 35.5 (0.11) 15.4 (0.06) 33.6 (0.09) 10.3 (0.06)
  1. a)Years; b) Months